Spero Therapeutics Inc (SPRO) - Total Assets
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) holds total assets worth $68.92 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SPRO capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Spero Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check Spero Therapeutics Inc (SPRO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Spero Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Spero Therapeutics Inc's total assets of $68.92 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.4% |
| Accounts Receivable | $25.39 Million | 36.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Spero Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Spero Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Spero Therapeutics Inc's current assets represent 97.6% of total assets in 2025, an increase from 83.4% in 2015.
- Cash Position: Cash and equivalents constituted 58.4% of total assets in 2025, down from 79.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 36.8% of total assets.
Spero Therapeutics Inc Competitors by Total Assets
Key competitors of Spero Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Spero Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.59 | 2.19 | 7.29 |
| Quick Ratio | 7.59 | 2.19 | 7.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $58.42 Million | $58.20 Million | $111.73 Million |
Spero Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Spero Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.51 |
| Latest Market Cap to Assets Ratio | 1.77 |
| Asset Growth Rate (YoY) | -37.7% |
| Total Assets | $68.92 Million |
| Market Capitalization | $122.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values Spero Therapeutics Inc's assets above their book value (1.77x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Spero Therapeutics Inc's assets decreased by 37.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Spero Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Spero Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $68.92 Million | -37.65% |
| 2024-12-31 | $110.54 Million | -39.39% |
| 2023-12-31 | $182.39 Million | +46.14% |
| 2022-12-31 | $124.80 Million | -27.05% |
| 2021-12-31 | $171.07 Million | +11.48% |
| 2020-12-31 | $153.45 Million | +44.62% |
| 2019-12-31 | $106.10 Million | -17.75% |
| 2018-12-31 | $129.01 Million | +38.01% |
| 2017-12-31 | $93.48 Million | +578.76% |
| 2016-12-31 | $13.77 Million | +91.92% |
| 2015-12-31 | $7.18 Million | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more